Finance

Lists
LLY80:BKK
Eli Lilly And Company KTB DR
฿1,95
-1,52%
(-0,030) 1D
1 Okt., 19:18:54 GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for LLY80...
Open
฿1,96
High
฿2,02
Low
฿1,94
Mkt. cap
1,09 bn
Avg. vol.
4,87 m
Volume
12,16 m
52-wk high
฿2,12
52-wk low
฿1,18
Shares outstanding
941,36 m
No. of employees
50 k
Open
฿1,96
High
฿2,02
Low
฿1,94
Mkt. cap
1,09 bn
Avg. vol.
4,87 m
Volume
12,16 m
52-wk high
฿2,12
52-wk low
฿1,18
Shares outstanding
941,36 m
No. of employees
50 k
News stories
From web sources and news partners
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company KTB DR
CEODavid A. Ricks
Employees50 k
Founded1876
HeadquartersIndianapolis, Indiana, Verenigde State van Amerika
SectorPharmaceutical industry
Websitelilly.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
17,60 mjd
19,29 mjd
19,80 mjd
22,97 mjd
Cost of goods sold
3,01 mjd
3,37 mjd
3,58 mjd
3,27 mjd
Cost of revenue
3,01 mjd
3,37 mjd
3,58 mjd
3,27 mjd
Research and development expenses
3,47 mjd
3,80 mjd
3,51 mjd
3,82 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,63 mjd
3,46 mjd
2,93 mjd
3,43 mjd
Operating expense
6,09 mjd
7,26 mjd
6,44 mjd
7,25 mjd
Total operating expenses
9,10 mjd
10,63 mjd
10,02 mjd
10,52 mjd
Operating income
8,50 mjd
8,66 mjd
9,78 mjd
12,46 mjd
Other non operating income
-9,10 m
181,20 m
170,00 m
561,00 m
EBT including unusual items
7,23 mjd
8,27 mjd
8,85 mjd
9,25 mjd
EBT excluding unusual items
8,21 mjd
8,89 mjd
9,71 mjd
12,73 mjd
Income tax expense
1,65 mjd
1,63 mjd
1,45 mjd
2,15 mjd
Effective tax rate
22,81%
19,70%
16,43%
23,27%
Other operating expenses
-
-
-
-
Net income
5,58 mjd
6,64 mjd
7,40 mjd
7,10 mjd
Net profit margin
31,72%
34,41%
37,36%
30,88%
Earnings per share
7,02
7,54
8,55
8,38
Interest and investment income
65,00 m
672,40 m
-
-
Interest expense
-179,60 m
-153,30 m
-332,00 m
-345,00 m
Net interest expenses
-114,60 m
519,10 m
-332,00 m
-345,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
8,97 mjd
9,25 mjd
10,29 mjd
12,99 mjd
Gain or loss from assets sale
-
-180,00 m
-
-
AI content may include mistakes. Learn more
Google-programme